Sichuan Medshine Pharmaceutical

Sichuan Medshine Pharmaceutical is a prominent Chinese biopharmaceutical company and a key subsidiary of the Haisco Pharmaceutical Group. The company specializes in the discovery, development, and commercialization of innovative small molecule therapeutics, with a primary focus on anesthesia, pain management, and metabolic diseases. Its flagship product, Ciprofol (HSK3486), is a novel anesthetic agent that has gained significant market traction in China as an alternative to propofol. Medshine maintains a robust pipeline featuring several late-stage candidates, including treatments for neuropathic pain, chronic kidney disease-associated pruritus, and type 2 diabetes. Leveraging its integrated R&D and high-standard manufacturing capabilities, the company is actively expanding its portfolio into advanced modalities such as PROTACs for oncology.